For the past three decades, apolipoprotein E (APOE) has been known as the single greatest
genetic modulator of sporadic Alzheimer disease (AD) risk, influencing both the average age …

The ɛ4 allele of the apolipoprotein E gene (APOE), which translates to the APOE4 isoform,
is the strongest genetic risk factor for late-onset Alzheimer disease (AD). Within the CNS …

Microglial involvement in Alzheimer's disease (AD) pathology has emerged as a risk-
determining pathogenic event. While apolipoprotein E (APOE) is known to modify AD risk, it …

APOE4 is the strongest genetic risk factor for Alzheimer's disease (AD), with increased odds
ratios in female carriers. Targeting amyloid plaques shows modest improvement in male non …

Microglia are central players in Alzheimer's disease pathology but analyzing microglial
states in human brain samples is challenging due to genetic diversity, postmortem delay and …

Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized
pathologically by extracellular deposition of β-amyloid (Aβ) into senile plaques and …

Background Recent trials of anti-amyloid-β (Aβ) monoclonal antibodies, including
lecanemab and donanemab, in early Alzheimer disease (AD) showed that these drugs have …

Recent discoveries of rare variants of human APOE may shed light on novel therapeutic
strategies for Alzheimer's disease (AD). Here, we highlight the newly identified protective …

Recent genetic studies on Alzheimer's disease (AD) have brought microglia under the
spotlight, as loci associated with AD risk are enriched in genes expressed in microglia …

The major genetic risk factor for Alzheimer's disease (AD), APOE4, accelerates beta-amyloid
(Aβ) plaque formation, but whether this is caused by APOE expressed in microglia or …